Cargando…

Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier

There is an urgent and unmet need to develop effective therapies for triple negative breast cancers (TNBCs) which are much more aggressive and have poor prognosis due to lack of receptor targets for Her2-targeted and endocrine therapy. In this study we systematically evaluated the effect of Vorinost...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Weina, Sun, Jingjing, Xu, Jieni, Luo, Zhangyi, Diao, Dingwei, Zhang, Ziqian, Oberly, Patrick J., Minnigh, Margaret Beth, Xie, Wen, Poloyac, Samuel M, Huang, Yi, Li, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052901/
https://www.ncbi.nlm.nih.gov/pubmed/32194813
http://dx.doi.org/10.7150/thno.38973
_version_ 1783502940538929152
author Ma, Weina
Sun, Jingjing
Xu, Jieni
Luo, Zhangyi
Diao, Dingwei
Zhang, Ziqian
Oberly, Patrick J.
Minnigh, Margaret Beth
Xie, Wen
Poloyac, Samuel M
Huang, Yi
Li, Song
author_facet Ma, Weina
Sun, Jingjing
Xu, Jieni
Luo, Zhangyi
Diao, Dingwei
Zhang, Ziqian
Oberly, Patrick J.
Minnigh, Margaret Beth
Xie, Wen
Poloyac, Samuel M
Huang, Yi
Li, Song
author_sort Ma, Weina
collection PubMed
description There is an urgent and unmet need to develop effective therapies for triple negative breast cancers (TNBCs) which are much more aggressive and have poor prognosis due to lack of receptor targets for Her2-targeted and endocrine therapy. In this study we systematically evaluated the effect of Vorinostat (SAHA, a pan-HDAC inhibitor) in reactivating the expression of functional estrogen receptor α (ERα) and synergizing with tamoxifen (TAM, a selective estrogen-receptor modulator) in antitumor activity. In addition, a SAHA prodrug-based dual functional nanocarrier was developed for codelivery of SAHA and TAM for effective combination therapy. Methods: A SAHA-containing polymeric nanocarrier, POEG-co-PVDSAHA was developed via reversible addition-fragmentation transfer (RAFT) polymerization with SAHA incorporated into the polymer through a redox-responsive disulfide linkage. The effect of both free SAHA and POEG-co-PVDSAHA on reactivating the expression of functional ERα was investigated in several human and murine TNBC cell lines via examining the mRNA and protein expression of ERα target genes. The cytotoxicity of free SAHA and TAM combination and TAM-loaded POEG-co-PVDSAHA micelles was examined via MTT assay. The in vivo antitumor activity of TAM-loaded POEG-co-PVDSAHA was investigated in a murine breast cancer model (4T1.2). Results: Both free SAHA and POEG-co-PVDSAHA were effective in inducing the reexpression of functional estrogen receptor α (ERα), which may have helped to sensitize TNBCs to TAM. More importantly, POEG-co-PVDSAHA self-assembled to form small-sized micellar carrier that is effective in formulating and codelivery of TAM. TAM-loaded POEG-co-PVDSAHA micelles exhibited enhanced and synergistic cytotoxicity against TNBC cell lines compared with free SAHA, free TAM and TAM loaded into a pharmacologically inert control carrier (POEG-co-PVMA). In addition, codelivery of TAM via POEG-co-PVDSAHA micelles led to significantly improved antitumor efficacy in 4T1.2 tumor model compared with other groups such as combination of free SAHA and TAM and TAM-loaded POEG-co-PVMA micelles. Conclusion: Our prodrug-based co-delivery system may provide an effective and simple strategy to re-sensitize TNBCs to TAM-based hormone therapy.
format Online
Article
Text
id pubmed-7052901
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-70529012020-03-19 Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier Ma, Weina Sun, Jingjing Xu, Jieni Luo, Zhangyi Diao, Dingwei Zhang, Ziqian Oberly, Patrick J. Minnigh, Margaret Beth Xie, Wen Poloyac, Samuel M Huang, Yi Li, Song Theranostics Research Paper There is an urgent and unmet need to develop effective therapies for triple negative breast cancers (TNBCs) which are much more aggressive and have poor prognosis due to lack of receptor targets for Her2-targeted and endocrine therapy. In this study we systematically evaluated the effect of Vorinostat (SAHA, a pan-HDAC inhibitor) in reactivating the expression of functional estrogen receptor α (ERα) and synergizing with tamoxifen (TAM, a selective estrogen-receptor modulator) in antitumor activity. In addition, a SAHA prodrug-based dual functional nanocarrier was developed for codelivery of SAHA and TAM for effective combination therapy. Methods: A SAHA-containing polymeric nanocarrier, POEG-co-PVDSAHA was developed via reversible addition-fragmentation transfer (RAFT) polymerization with SAHA incorporated into the polymer through a redox-responsive disulfide linkage. The effect of both free SAHA and POEG-co-PVDSAHA on reactivating the expression of functional ERα was investigated in several human and murine TNBC cell lines via examining the mRNA and protein expression of ERα target genes. The cytotoxicity of free SAHA and TAM combination and TAM-loaded POEG-co-PVDSAHA micelles was examined via MTT assay. The in vivo antitumor activity of TAM-loaded POEG-co-PVDSAHA was investigated in a murine breast cancer model (4T1.2). Results: Both free SAHA and POEG-co-PVDSAHA were effective in inducing the reexpression of functional estrogen receptor α (ERα), which may have helped to sensitize TNBCs to TAM. More importantly, POEG-co-PVDSAHA self-assembled to form small-sized micellar carrier that is effective in formulating and codelivery of TAM. TAM-loaded POEG-co-PVDSAHA micelles exhibited enhanced and synergistic cytotoxicity against TNBC cell lines compared with free SAHA, free TAM and TAM loaded into a pharmacologically inert control carrier (POEG-co-PVMA). In addition, codelivery of TAM via POEG-co-PVDSAHA micelles led to significantly improved antitumor efficacy in 4T1.2 tumor model compared with other groups such as combination of free SAHA and TAM and TAM-loaded POEG-co-PVMA micelles. Conclusion: Our prodrug-based co-delivery system may provide an effective and simple strategy to re-sensitize TNBCs to TAM-based hormone therapy. Ivyspring International Publisher 2020-01-20 /pmc/articles/PMC7052901/ /pubmed/32194813 http://dx.doi.org/10.7150/thno.38973 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Ma, Weina
Sun, Jingjing
Xu, Jieni
Luo, Zhangyi
Diao, Dingwei
Zhang, Ziqian
Oberly, Patrick J.
Minnigh, Margaret Beth
Xie, Wen
Poloyac, Samuel M
Huang, Yi
Li, Song
Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
title Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
title_full Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
title_fullStr Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
title_full_unstemmed Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
title_short Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier
title_sort sensitizing triple negative breast cancer to tamoxifen chemotherapy via a redox-responsive vorinostat-containing polymeric prodrug nanocarrier
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052901/
https://www.ncbi.nlm.nih.gov/pubmed/32194813
http://dx.doi.org/10.7150/thno.38973
work_keys_str_mv AT maweina sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT sunjingjing sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT xujieni sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT luozhangyi sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT diaodingwei sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT zhangziqian sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT oberlypatrickj sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT minnighmargaretbeth sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT xiewen sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT poloyacsamuelm sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT huangyi sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier
AT lisong sensitizingtriplenegativebreastcancertotamoxifenchemotherapyviaaredoxresponsivevorinostatcontainingpolymericprodrugnanocarrier